SAM
RPRX icon

SEB Asset Management’s Royalty Pharma RPRX Stock Holding History

SEB Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.8M Buy
443,035
+172,726
+64% +$8.99M 0.09% 191
2026
Q1 		$13M Buy
+270,309
New +$11.8M 0.06% 277

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

SEB Asset Management's RPRX Position: Q2 2026 in Review

SEB Asset Management increased its Royalty Pharma (RPRX) stake by 64% in Q2 2026, buying an estimated $8.99M and bringing the position to 443,035 shares worth $24.8M. The position accounts for 0.09% of the portfolio, ranked #191.

SEB Asset Management first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 607 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • SEB Asset Management held 443,035 shares of Royalty Pharma worth $24.8M as of Q2 2026.
  • SEB Asset Management bought 172,726 Royalty Pharma shares in Q2 2026, an estimated $8.99M.
  • Royalty Pharma made up 0.09% of SEB Asset Management's portfolio in Q2 2026, its #191 holding.
  • SEB Asset Management first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • 607 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.